All News

The real-world study of 200,000+ adults found no GI safety differences among 3 GLP-1 drugs for T2D, however SGLT-2 inhibitors are safer for motility issues.

WAYFINDER: 90% of steroid-dependent severe asthma patients reduced to ≤5mg daily on tezepelumab. Well-controlled asthma increased from 3% to 27% at 52 weeks.

Three-biomarker panel independently predicted cardiovascular events over 20 years in European cohort, with highest risk when all 3 were elevated.

A quick quiz covering new research on menopause hormone therapy, Alzheimer risk, tirzepatide weight loss, and estetrol’s cardiovascular safety.

The rate of AF recurrence was reduced significantly and participants also experienced improvements in self-reported AF severity as well as improved cardiometabolic measures.

Genitourinary symptoms of menopause often are ignored--by patients and practitioners alike. Primary care clinicians are in a key position to identify, educate, and initiate treatment.

TMS 2025: Donna Plecha, MD, discusses how primary care physicians should approach breast cancer screening in women with dense breasts and use MRI effectively.

Use of GLP-1 receptor agonists for weight loss has more than doubled since early 2024 while 7.6 million fewer US adults qualify as obese in 2025.

TMS 2025: Jiang explains why he investigated hormone therapy's effect on autoimmune disease risk in postmenopausal women.